[Baiyunshan: Subsidiary Guangzhou Pharmaceutical plans to publicly list to introduce strategic investment and directional stock issuance to raise no more than 6 billion yuan] On November 9, Baiyunshan (600332.SH) announced that the company’s controlled subsidiary Guangzhou Pharmaceutical plans to pass Guangzhou Equity Transaction The company is publicly listed to introduce strategic investors and implement directional issuance of stocks. It plans to recruit no more than 15 investors, the issuance price is not less than 3.46 yuan per share, the directional issuance of stocks does not exceed 1.734 billion shares, and the scale of raised funds does not exceed 6 billion yuan. After the completion of this capital increase and share expansion, it is expected that the company will hold no less than 53.23% of the equity of Guangzhou Pharmaceutical and will remain its controlling shareholder, which will not result in a change in the scope of the consolidated statements. The funds raised will be used to supplement working capital and repay bank loans. This capital increase and share expansion still need to be submitted to the company's shareholders' meeting for review. There is uncertainty about whether the strategic investment can be successfully introduced and the final amount.